Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Alzheimer's Medication Trials

Rhode Island

Alzheimer's medication trials in Rhode Island

6 Alzheimer's medication studies are recruiting participants at sites in 2 cities across Rhode Island as of November 17, 2026, according to ClinicalTrials.gov.

Call (888) 927-5916
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Every Rhode Island city with a recruiting study

Providence (4), East Providence (2).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Recently updated studies in Rhode Island

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

    • Phase 3
    • Ages 60 to 85
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Recruiting in
    East Providence
    Registry record
    NCT06976216 · updated
  2. A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease

    • Phase 2
    • Ages 55 to 85
    • All sexes
    Sponsor
    Sanofi
    Recruiting in
    East Providence
    Registry record
    NCT07688213 · updated
  3. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Recruiting in
    Providence
    Registry record
    NCT06585787 · updated
  4. Alzheimer's Tau Platform: Master Protocol

    • Phase 2
    • Ages 50 to 80
    • All sexes
    Sponsor
    Paul S. Aisen
    Recruiting in
    Providence
    Registry record
    NCT06957418 · updated
  5. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Washington University School of Medicine
    Recruiting in
    Providence
    Registry record
    NCT05552157 · updated
  6. A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Washington University School of Medicine
    Recruiting in
    Providence
    Registry record
    NCT06647498 · updated

Source: ClinicalTrials.gov. Data processed . See every Alzheimer's disease study recruiting in Rhode Island on ClinicalTrials.gov.

Ask about studies in Rhode Island

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.

Alzheimer's Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5916

or send a short form

How should we reach you?

Call